Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HCA Health Inc (HCA) vs Live Nation Entertainment, Inc. (LYV) Price & Performance

HCA Health IncTrade
Live Nation Entertainment, Inc.Trade

Price performance (Past 24H)

Key statistics

HCA Health Inc vs Live Nation Entertainment, Inc. — how do they compare? HCA Health Inc trades at $443.69 (market cap $95.08B), while Live Nation Entertainment, Inc. trades at $171.11 (market cap $39.80B). The key difference: HCA Health Inc is far larger — about 2.4× Live Nation Entertainment, Inc.'s market cap, and HCA Health Inc pays a 0.71% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Live Nation Entertainment, Inc. for 72 Days on average.

HCALYV
Market Cap
$95.08B$39.80B
Volume
998,7871,162,440
Sector
HealthMedia
52-Week High
$545.13$188.46
52-Week Low
$361.32$125.61
Typical Hold Time
76 Days72 Days
Enterprise Value
$145.62B$42.01B
Dividend Yield
0.71%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HCA Health Inc

HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.

The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.

Live Nation Entertainment, Inc.

Live Nation Entertainment (LYV) trades at $171.34, down 0.26% on the day, with a bullish technical signal and strong analyst support (87% buy ratings). The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.5 and negative ROE of -116.7%. Recent news highlights strong consumer demand for live events and strategic partnerships, though regulatory scrutiny and insider selling warrant attention.

The outlook remains positive given robust fan attendance and deferred revenue growth, but high valuation and execution risks in a seasonally heavy Q4 present challenges. Wall Street's $208 price target suggests 21% upside, positioning LYV as a growth play on experiential spending trends with balanced risk-reward dynamics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HCA
100% Buy0% Sell
Avg holding period · 76 Days
LYV

No sentiment data available yet.

Top news

Latest headlines on both assets

About HCA Health Inc

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.

Read more on HCA →

About Live Nation Entertainment, Inc.

Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.

Read more on LYV →